Stelic Institute & Co. - Product Pipeline Review - 2012

Stelic Institute & Co. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Stelic Institute & Co. - Product Pipeline Review - 2012” provides data on the Stelic Institute & Co.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Stelic Institute & Co.’s corporate website, SEC filings, investor presentations and featured press releases, both from Stelic Institute & Co. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Stelic Institute & Co. - Brief Stelic Institute & Co. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Stelic Institute & Co. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Stelic Institute & Co. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Stelic Institute & Co.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Stelic Institute & Co.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Stelic Institute & Co. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Stelic Institute & Co.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Stelic Institute & Co..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Stelic Institute & Co. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Stelic Institute & Co.; Stelic Institute & Co. - Key Therapeutics; Stelic Institute & Co. - Pipeline Overview and Promising Molecules; Stelic Institute & Co. - News; Stelic Institute & Co. - Latest Updates; Stelic Institute & Co. - Pipeline; Stelic Institute & Co. - Discontinued/Dormant Projects SHOW LESS READ MORE >

2
List of Tables 4
List of Figures 4
Stelic Institute & Co. Snapshot 5
Stelic Institute & Co. Overview 5
Key Information 5
Key Facts 5
Stelic Institute & Co. – Research and Development Overview 6
Key Therapeutic Areas 6
Stelic Institute & Co. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Stelic Institute & Co. – Pipeline Products Glance 11
Stelic Institute & Co. – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Stelic Institute & Co. – Drug Profiles 13
G Family Inhibitor For CKD 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
G Family Inhibitor For COPD 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
G Family Inhibitor For Dementia 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
G Family Inhibitor For Diabetic Retinopathy 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
G Family Inhibitor For NASH 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
G Family Inhibitor For Type 2 Diabetes And Chronic Pancreatitis 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
G Family Inhibitors For Parkinson's Disease And Alzheimer’s Disease 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
STNM01 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
STNM04 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Stelic Institute & Co. – Pipeline Analysis 22
Stelic Institute & Co. – Pipeline Products by Therapeutic Class 22
Stelic Institute & Co. – Pipeline Products By Target 24
Stelic Institute & Co. – Pipeline Products by Route of Administration 25
Stelic Institute & Co. – Pipeline Products By Mechanism of Action 26
Stelic Institute & Co. – Locations And Subsidiaries 27
Head Office 27
Financial Deals Landscape 28
Stelic Institute & Co., Deals Summary 28
Stelic Institute & Co., Pharmaceuticals & Healthcare, Deal Details 29
Partnerships 29
Stelic Institute Enters Into Research Collaboration With Niigata University Medical and Dental Hospital 29
Stelic Institute Enters Into Research Collaboration With Niigata University 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Stelic Institute & Co., Key Information 5
Stelic Institute & Co., Key Facts 5
Stelic Institute & Co. – Pipeline by Indication, 2012 8
Stelic Institute & Co. – Pipeline by Stage of Development, 2012 9
Stelic Institute & Co. – Monotherapy Products in Pipeline, 2012 10
Stelic Institute & Co. – Pre-Clinical, 2012 11
Stelic Institute & Co. – Discovery, 2012 12
Stelic Institute & Co. – Pipeline By Therapeutic Class, 2012 23
Stelic Institute & Co. - Pipeline By Target, 2012 24
Stelic Institute & Co. – Pipeline By Route of Administration, 2012 25
Stelic Institute & Co. – Pipeline Products By Mechanism of Action, 2012 26
Stelic Institute & Co., Deals Summary 28
Stelic Institute Enters Into Research Collaboration With Niigata University Medical and Dental Hospital 29
Stelic Institute Enters Into Research Collaboration With Niigata University 30

List of Figures
Stelic Institute & Co. – Pipeline by Indication, 2012 7
Stelic Institute & Co. – Pipeline by Stage of Development, 2012 9
Stelic Institute & Co. – Monotherapy Products in Pipeline, 2012 10
Stelic Institute & Co. – Pipeline By Therapeutic Class, 2012 22
Stelic Institute & Co. - Pipeline By Target, 2012 24